(Date:12/16/2009)... conducted pursuant to Special Protocol Assessment with ... CITY, Dec. 16 /PRNewswire-FirstCall/ - AEterna Zentaris ... (the "Company"), a global biopharmaceutical company focused ... the initiation, by its partner Keryx Biopharmaceuticals ... 3 registration clinical trial for perifosine (KRX-0401), ...
(Date:12/16/2009)... HSP-A Soy Peptone. HSP A has been found to be ... ... (PRWEB) December 16, 2009 -- Nu-Tek BioSciences, LLC. ( www.nu-tekproducts.com ) ... Peptone. HSP-A, previously manufactured by Nutricepts, Inc. (Burnsville, Mn), is ... growth rates and yields. HSP-A has been found to be ...
(Date:12/15/2009)... (JBEI), one of three Department of Energy (DOE) bio-energy ... to protect its valuable intellectual property. , ... ... 15, 2009 -- Surety, LLC , the leading ... announced that the Joint BioEnergy Institute (JBEI), one of ...
(Date:12/15/2009)... Reportlinker.com announces that a new ... catalogue: ,, The Future of ... 2015, Pipeline Analysis and Reimbursement ... ,, Summary ,, The author ... of Orphan Diseases Therapeutics - Market Forecasts ...
Breaking Biology Technology:AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 2AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 3AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 4AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 5Joint BioEnergy Institute Selects Surety's AbsoluteProof to Protect the Integrity and Legally Defend the Authenticity of its Scientific Intellectual Property 2Joint BioEnergy Institute Selects Surety's AbsoluteProof to Protect the Integrity and Legally Defend the Authenticity of its Scientific Intellectual Property 3Joint BioEnergy Institute Selects Surety's AbsoluteProof to Protect the Integrity and Legally Defend the Authenticity of its Scientific Intellectual Property 4Joint BioEnergy Institute Selects Surety's AbsoluteProof to Protect the Integrity and Legally Defend the Authenticity of its Scientific Intellectual Property 5Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 2Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 3Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 4Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 5Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 6Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 7Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 8Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 9Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 10Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 11Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 12Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 13Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 14Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 15Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 16Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 17Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 18... attendees from 47 countries convene in Seattle for AIDS ... Vaccine ... researchers,clinicians, and specialists convene this week for the AIDS Vaccine 2007,Conference ... Conference in Paris, this event has emerged as the premier forum ...
... GeoVax Labs, Inc. (OTC,Bulletin Board: GOVX), an Atlanta-based ... provided an,operational update for the quarter ended June 30, ... 30, 2007 The Company recorded a net loss ... compared to net income of $197,750 for the same ...
... Aug. 14 Transgenomic, Inc. (the,"Company") (OTC Bulletin Board: ... 30, 2007. The Company,s financial results are,presented in the ... Company reported a net profit of $0.2 million or ... compared to a net loss of $0.4 million or,$0.01 ...
Other Biology Technology:Global Experts Explore Entire Spectrum of Aids Vaccine Development 2GeoVax Labs, Inc. Second Quarter Financial Results and Operational Update 2GeoVax Labs, Inc. Second Quarter Financial Results and Operational Update 3GeoVax Labs, Inc. Second Quarter Financial Results and Operational Update 4GeoVax Labs, Inc. Second Quarter Financial Results and Operational Update 5GeoVax Labs, Inc. Second Quarter Financial Results and Operational Update 6Transgenomic, Inc. Reports Second Quarter 2007 Results 2Transgenomic, Inc. Reports Second Quarter 2007 Results 3Transgenomic, Inc. Reports Second Quarter 2007 Results 4Transgenomic, Inc. Reports Second Quarter 2007 Results 5Transgenomic, Inc. Reports Second Quarter 2007 Results 6Transgenomic, Inc. Reports Second Quarter 2007 Results 7Transgenomic, Inc. Reports Second Quarter 2007 Results 8RABBIT ANTI ISOCITRATE DEHYDROGENASE...
Recombinant Equine TNF-alpha/TNFSF1A, CF...
Recombinant Feline IL-2, CF...
... and G. Butcher (1998). • The major ... research in the immunology area. There is ... proteins and in their function as antigen-presenting ... with the prospect of tackling biochemical and ...
Biology Products:Biology NavigationMedical Navigation